Alkermes plc. Gain (Loss) on Extinguishment of Debt
Alkermes plc. (ALKS) reported Gain (Loss) on Extinguishment of Debt of -$171.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2022-11-02
- Alkermes plc. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- Alkermes plc. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- Alkermes plc. gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $0.00.
- Alkermes plc. gain (loss) on extinguishment of debt for the quarter ending 2021-03-31 was -$171.00K.
- Alkermes plc. gain (loss) on extinguishment of debt for fiscal 2021 was -$171.00K.
- Alkermes plc. gain (loss) on extinguishment of debt for fiscal 2018 was -$2.30M.
- Alkermes plc. gain (loss) on extinguishment of debt for fiscal 2016 was -$2.08M.
- Alkermes plc. gain (loss) on extinguishment of debt for fiscal 2013 was -$19.67M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 derived: sum of 3 quarters · filed 2022-11-02 | -$171.00K 10-K · filed 2022-02-16 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | -$171.00K 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$171.00K 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | -$171.00K 10-Q · filed 2022-04-27 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $0.00 derived: sum of 3 quarters · filed 2021-02-11 | -$2.30M 10-K · filed 2021-02-11 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-23 | $0.00 derived: sum of 2 quarters · filed 2019-10-23 | -$2.30M 10-Q · filed 2019-10-23 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | -$2.30M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | -$2.30M 10-Q · filed 2019-04-25 | |||
| 2016-12-31 | -$2.08M 10-K · filed 2019-02-15 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | $0.00 derived: sum of 2 quarters · filed 2014-10-29 | -$7.54M 10-Q · filed 2014-10-29 | -$7.54M derived: sum of 4 quarters · filed 2014-10-29 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$7.54M 10-Q · filed 2014-07-31 | -$7.54M derived: sum of 3 quarters · filed 2014-07-31 | -$19.67M derived: sum of 4 quarters · filed 2014-07-31 |
| 2013-03-31 | -$7.54M 10-Q · filed 2014-04-30 | -$7.54M derived: sum of 2 quarters · filed 2014-04-30 | -$19.67M derived: sum of 3 quarters · filed 2014-04-30 | -$19.67M 10-K · filed 2015-02-24 |
| 2012-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | -$12.13M derived: sum of 2 quarters · filed 2013-01-31 | -$12.13M 10-Q · filed 2013-01-31 | |
| 2012-09-30 | -$12.13M 10-Q · filed 2013-01-31 | -$12.13M 10-Q · filed 2013-10-31 | ||
| 2011-03-31 | -$841.00K 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |